Nakajima T
Division of Gastrointestinal Tract Surgery, Cancer Institute Hospital, Tokyo, Japan.
World J Surg. 1995 Jul-Aug;19(4):570-4. doi: 10.1007/BF00294725.
Controlled randomized studies that compared surgery alone to adjuvant chemotherapy for gastric cancer were reviewed. The amount of residual tumor after surgery, selection of drug regimens, compliance with drug administration, and trial design seem to be responsible for the success of adjuvant chemotherapy. Though there are few beneficial regimens of adjuvant chemotherapy with statistical significance, single drug therapy with mitomycin C (MMC) and combination therapy with 5-fluorouracil (5FU) and methyl-CCNU, MMC/5FU/cytosine arabinoside (MFC), and 5FU/Adriamycin/MMC (FAM) seem to have potential survival benefit for patients with curative surgery. Incorporation of new drugs into adjuvant or neoadjuvant chemotherapy might open a new aspect of multimodality therapy for gastric cancer.
对比较单纯手术与辅助化疗治疗胃癌的对照随机研究进行了综述。手术后的残留肿瘤量、药物方案的选择、药物给药的依从性以及试验设计似乎是辅助化疗成功的原因。尽管具有统计学意义的辅助化疗有益方案很少，但丝裂霉素C（MMC）单药治疗以及5-氟尿嘧啶（5FU）与甲基环己亚硝脲联合治疗、MMC/5FU/阿糖胞苷（MFC）和5FU/阿霉素/MMC（FAM）联合治疗似乎对接受根治性手术的患者有潜在的生存益处。将新药纳入辅助或新辅助化疗可能为胃癌的多模式治疗开辟一个新的方向。
